All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @betsmarr on TikTok · 21s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @betsmarr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00You're down 34 pounds on Terzepata and today is injection day.
  2. 0:03I have been on GOP one for four months.
  3. 0:05My start weight was 171 and I am currently at 137.
  4. 0:09The only symptoms are nausea and being tired only the day after the shot.
  5. 0:14You have been thinking about getting on Terzepata.
  6. 0:16Then this is your side.
  7. 0:16Ask me any questions in the comments.
  8. 0:18The link is in my bio and use my code BEDS for $50 off.

@betsmarr's 34-pound tirzepatide loss claim, fact-checked

Bets

TikTok creator

245.1K viewsWatch on TikTok

Quick answer

The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial. She reports only next-day nausea and fatigue as side effects, which understates the adverse event profile documented in clinical trials and FDA labeling for tirzepatide. Her video also promotes a compounded tirzepatide platform, and viewers should understand that compounded formulations are not FDA-approved equivalents to Zepbound.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @betsmarr's 34-pound tirzepatide loss claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@betsmarr's 34-pound tirzepatide loss claim, fact-checked" from Bets. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial.

The reason this review is not generic is the source wording and the canonical claim label "glp1 down 34 pounds on tirz in my bio use code bets for." In this clip, the useful excerpt is: "You're down 34 pounds on Terzepata and today is injection day." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial. She reports only next-day nausea and fatigue as side effects, which understates the adverse event profile documented in clinical trials and FDA labeling for tirzepatide. Her video also promotes a compounded tirzepatide platform, and viewers should understand that compounded formulations are not FDA-approved equivalents to Zepbound.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of up to 20.9% of body weight over 72 weeks on 15 mg tirzepatide, making the creator's results plausible but not typical.
  • Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of up to 20.9% of body weight over 72 weeks on 15 mg tirzepatide, making the creator's results plausible but not typical.
  • Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.
  • SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who stopped tirzepatide regained a significant portion of lost weight, meaning this is not a short-term fix.
  • Compounded tirzepatide dispensed by telehealth platforms is not FDA-approved and has not been independently verified for potency, sterility, or equivalence to brand-name Zepbound.
  • The creator earns a financial benefit when viewers use her code, which is a material conflict of interest that should be disclosed prominently under FTC guidelines.
  • Muscle mass loss during GLP-1-assisted weight loss is a documented clinical concern. Resistance exercise and protein intake are recommended by obesity medicine specialists to mitigate it.
  • Anyone considering tirzepatide should consult a licensed clinician with access to their full medical history, not base a decision on a 60-second social media testimonial.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @betsmarr actually say?

The creator says she lost 34 pounds on tirzepatide over four months, dropping from 171 to 137 pounds. She describes her side effects as limited to "nausea and being tired only the day after the shot" and wraps up by directing viewers to a link in her bio with a discount code for a telehealth platform. That is the whole pitch: personal results, low downside, easy access.

She is clearly promoting a paid partnership with LifeRx.md, which matters for context. This is not a neutral testimonial. It is an affiliate arrangement, and viewers clicking her link help her earn money. The FTC requires this be disclosed clearly. A referral code and a platform tag in the caption is borderline disclosure at best.

Does the science back this up?

Her weight loss numbers are plausible and actually on the conservative side compared to trial data. Yes, the clinical evidence for tirzepatide is strong enough that downplaying it would be the bigger distortion.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest dose of tirzepatide (15 mg) lost a mean of 20.9% of body weight over 72 weeks. If her starting weight was 171 pounds, a 34-pound loss over four months at approximately 20% body weight is at the faster end but not outside what trials documented in earlier months of treatment. The SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) confirmed similar trajectories in people with obesity and type 2 diabetes. Four months is also roughly consistent with when patients hit meaningful weight loss milestones before the curve flattens.

What did they get wrong (or right)?

The side effect picture she paints is too clean, and that is a real problem. She says the "only symptoms are nausea and being tired only the day after the shot." That framing will mislead people.

SURMOUNT-1 reported that 4.3% of participants in the tirzepatide group discontinued due to adverse events, primarily gastrointestinal. Nausea affected roughly 30-40% of participants depending on dose, but vomiting, diarrhea, and constipation were also common. Pancreatitis, gallbladder disease, and heart rate increases are listed in the drug's labeling. None of that means tirzepatide is dangerous for everyone, but telling 245,000 viewers that side effects are just one tired day is genuinely irresponsible. It sets people up to either dismiss real symptoms or feel like something is wrong with them when they experience more than she did.

Her weight loss results and the four-month timeline, to her credit, are consistent with clinical data.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA as Zepbound for chronic weight management in adults with obesity or overweight with a weight-related condition. The drug works. The clinical evidence is among the strongest produced for a weight-loss medication in decades.

But individual results vary considerably. Factors like baseline metabolic health, dose titration schedule, diet, and adherence all affect outcomes. The creator's results are real to her. They are not a guarantee or even a reliable benchmark for anyone else.

Compounded tirzepatide, which is what many telehealth platforms dispense, is not the same as FDA-approved Zepbound. The FDA has stated that compounded drugs are not proven to be safe and effective in the same way as their approved counterparts. Patients should ask their prescriber specifically what they are being dispensed and understand that difference before starting.

  • Always disclose GLP-1 use to all your treating clinicians, not just the telehealth platform.
  • Muscle loss is a documented concern with rapid weight loss on GLP-1 medications. Resistance training and adequate protein intake matter.
  • Stopping the medication abruptly is associated with weight regain, as shown in the SURMOUNT-4 trial (Aronne et al., 2024, JAMA).

Should you trust this video?

Trust the basic weight loss claim as plausible. Do not trust the side effect claim as representative. And recognize that the person telling you this gets paid when you use her code. That does not make her experience fake, but it does make the framing a sales pitch, not medical advice. Talk to a licensed clinician who has access to your full health history before starting any GLP-1 therapy.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Bets · TikTok creator

245.1K views on this video

Down 34 pounds on tirz 🥳 🔗 in my bio + use code bets for an extra $50 off @liferx.md #weightlossmotivation #weightloss #weightlossjouney #tirzepatidejourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed mean weight loss?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of up to 20.9% of body weight over 72 weeks on 15 mg tirzepatide, making the creator's results plausible but not typical.

What does the video say about tirzepatide's fda label lists nausea, vomiting, diarrhea, constipation, abdominal pain,?

Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.

What does the video say about surmount-4 (aronne et al., 2024, jama) found?

SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who stopped tirzepatide regained a significant portion of lost weight, meaning this is not a short-term fix.

What does the video say about compounded tirzepatide dispensed by telehealth platforms?

Compounded tirzepatide dispensed by telehealth platforms is not FDA-approved and has not been independently verified for potency, sterility, or equivalence to brand-name Zepbound.

What does the video say about the creator earns a financial benefit?

The creator earns a financial benefit when viewers use her code, which is a material conflict of interest that should be disclosed prominently under FTC guidelines.

What does the video say about muscle mass loss during glp-1-assisted weight loss?

Muscle mass loss during GLP-1-assisted weight loss is a documented clinical concern. Resistance exercise and protein intake are recommended by obesity medicine specialists to mitigate it.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Bets, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.